MDACC Study No:2013-0843 ( NCT No: NCT02096055)
Title:Four-Arm Randomized Phase II Study of SGI-110: 5 days, versus 10 days, versus 5 days + idarubicin, versus 5 days + cladribine, in Previously Untreated Patients >/= 70 Years with Acute Myeloid Leukemia
Principal Investigator:Hagop Kantarjian
Treatment Agent:Cladribine; Idarubicin; SGI-110
Study Status:Open
Study Description:The goal of this clinical research study is to compare different treatment
schedules using the drug SGI-110 alone or in combination with other drugs.
Researchers want to learn more about how these different treatment schedules
may help to control AML. The safety of these treatments will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cladribine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Astex
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults